Skip to main content

 Related scientific articles (all)

Reactive stroma and trastuzumab resistance in HER2-positive early breast cancer.

Authors : Sonnenblick A, Salmon-Divon M, Salgado R, Dvash E, Pondé N, Zahavi T, Salmon A, Loibl S, Denkert C, Joensuu H, Ameye L, Van den Eynden G, Kellokumpu-Lehtinen PL, Azaria A, Loi S, Michiels S, Richard F, Sotiriou C
Year : 2020
Journal : Int J Cancer
Volume : 147
Pages : 266-276

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer.

Authors : Hunter FW, Barker HR, Lipert B, Rothé F, Gebhart G, Piccart-Gebhart MJ, Sotiriou C, Jamieson SMF
Year : 2020
Journal : Br J Cancer
Volume : 122
Pages : 603-612

Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.

Authors : Bareche Y, Buisseret L, Gruosso T, Girard E, Venet D, Dupont F, Desmedt C, Larsimont D, Park M, Rothé F, Stagg J, Sotiriou C
Year : 2020
Journal : J Natl Cancer Inst
Volume : 112
Pages : 708-719

Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Authors : Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G
Year : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 354-363

Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.

Authors : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart M, de Azambuja E
Year : 2020
Journal : J Natl Cancer Inst

Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations.

Authors : Lambertini M, Ameye L, Hamy AS, Zingarello A, Poorvu PD, Carrasco E, Grinshpun A, Han S, Rousset-Jablonski C, Ferrari A, Paluch-Shimon S, Cortesi L, Senechal C, Miolo G, Pogoda K, Pérez-Fidalgo JA, De Marchis L, Ponzone R, Livraghi L, Estevez-Diz MDP, Villarreal-Garza C, Dieci MV, Clatot F, Berlière M, Graffeo R, Teixeira L, Córdoba O, Sonnenblick A, Luna Pais H, Ignatiadis M, Paesmans M, Partridge AH, Caron O, Saule C, Del Mastro L, Peccatori FA, Azim HA Jr
Year : 2020
Journal : J Clin Oncol
Pages : JCO1902399

Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index.

Authors : Desmedt C, Fornili M, Clatot F, Demicheli R, De Bortoli D, Di Leo A, Viale G, de Azambuja E, Crown J, Francis PA, Sotiriou C, Piccart M, Biganzoli E
Year : 2020
Journal : J Clin Oncol
Pages : JCO1901771

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis.

Authors : Brandão M, Maurer C, Ziegelmann PK, Pondé NF, Ferreira A, Martel S, Piccart M, de Azambuja E, Debiasi M, Lambertini M
Year : 2020
Journal : ESMO Open
Volume : 5

Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer.

Authors : Demicheli R, Desmedt C, Retsky M, Sotiriou C, Piccart-Gebhart M, Biganzoli E
Year : 2020
Journal : Breast
Volume : 52
Pages : 64-70

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Authors : Hudecek J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 15

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

Authors : Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Lænkholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudecek J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klaushen F, Cooper L, Amgad M, Moore DA, Salgado R
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 17

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

Authors : Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudecek J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez-Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD
Year : 2020
Journal : NPJ Breast Cancer
Volume : 6
Pages : 16

Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome.

Authors : Venet D, Fimereli D, Rothé F, Boeckx B, Maetens M, Majjaj S, Rouas G, Capra M, Bonizzi G, Contaldo F, Galant C, Piccart M, Pruneri G, Larsimont D, Lambrechts D, Desmedt C, Sotiriou C
Year : 2020
Journal : EBioMedicine
Volume : 56
Pages : 102793

Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.

Authors : Van Marcke C, Helaers R, De Leener A, Merhi A, Schoonjans CA, Ambroise J, Galant C, Delrée P, Rothé F, Bar I, Khoury E, Brouillard P, Canon JL, Vuylsteke P, Machiels JP, Berlière M, Limaye N, Vikkula M, Duhoux FP
Year : 2020
Journal : Breast Cancer Res
Volume : 22
Pages : 36

Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors.

Authors : Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brandão M, de Angelis C, Hendlisz A, Awada A, Piccart-Gebhart M, de Azambuja E
Year : 2020
Journal : Breast Cancer Res Treat

Prognostic and Predictive Impact of Beta-2 Adrenergic Receptor Expression in HER2-Positive Breast Cancer.

Authors : Caparica R, Richard F, Brandão M, Awada A, Sotiriou C, de Azambuja E
Year : 2020
Journal : Clin Breast Cancer

Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer.

Authors : Eiger D, Brandão M, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

The core spliceosomal factor U2AF1 controls cell-fate determination via the modulation of transcriptional networks.

Authors : Laaref AM, Manchon L, Bareche Y, Lapasset L, Tazi J
Year : 2020
Journal : RNA Biol
Pages : 1-15

Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials.

Authors : Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E
Year : 2020
Journal : ESMO Open
Volume : 5

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.

Authors : Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Lænkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M
Year : 2020
Journal : J Pathol
Volume : 250
Pages : 667-684